Dnah9 mutant mice and organoid models recapitulate the clinical features of patients with PCD and provide an excellent platform for drug screening Research Published on 2022-06-212022-10-05 Journal: Cell Death & Disease [Category] 변종, [키워드] affected airway Analysis Arm Bioinformatic can be used cause caused ciliary clinical feature co-immunoprecipitation demonstrated DNAH9 drug Drug screening etiology expression feature functional genetic disease identify Immune cell infiltration infections lack lung failure Lung function mice mimicking mutant Mutation outcome Pathogenesis Patient patients performed Phenotypes platform Protein protein levels randomization Respiratory tract infections responsible shown the patient Therapies western blot Western blot analysis [DOI] 10.1038/s41419-022-05010-5 [Article Type] Research
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trialRandomized Controlled Trial Published on 2022-04-272022-10-04 Journal: Trials [Category] 임상, [키워드] 7-point ordinal scale adaptive Adaptive sample size addition Analysis analysis plan angiotensin angiotensin receptor blocker Angiotensin receptor blockers Bayesian Bayesian design benefit blocker CLARITY clinical clinical status clinical trial Controlled coronavirus COVID-19 determine disease Effectiveness Evidence India intention-to-treat principle lung failure patients with COVID-19 Placebo primary analysis Primary outcome protocol randomised controlled randomised controlled trial receptor reducing registry Sample size severity standard care Statistical analysis plan Statistical analysis plan. the WHO Treatment effectiveness Trial Two-arm was selected [DOI] 10.1186/s13063-022-06167-2 PMC 바로가기 [Article Type] Randomized Controlled Trial
Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic managementReview Published on 2021-12-062022-10-28 Journal: Pneumonia [Category] COVID-19, [키워드] acute respiratory distress syndrome adverse effects approved ARDS ARDS patients clinical trial COVID-19 COVID-19 pandemic COVID-19 patients COVID-19 vaccination distress Effect effective Efficacy evaluated experimental drug FDA help ICU immunopathology intensive care Lung disease lung failure management mechanism Multiple Pandemics patients patients with COVID-19 Potential treatment Probably SARS-CoV-2 sick syndrome therapeutic therapy Treatment treatment strategy [DOI] 10.1186/s41479-021-00092-9 PMC 바로가기 [Article Type] Review
Pneumomediastinum and Pneumothorax as Relevant Complications of Sub-Intensive Care of Patients with COVID-19: Description of a Case SeriesBrief Report Published on 2021-09-012022-10-30 Journal: Medicina [Category] COVID-19, SARS, [키워드] clinical experience Cohort Complication COVID-19 described description develop Diseases Hospitalization Hospitalized illness Inpatient Inpatients interstitial pneumonia lung failure non-invasive ventilation Occurrence Pneumomediastinum Pneumothorax Prognosis Pulmonary embolism Sery with COVID-19 worsening [DOI] 10.3390/medicina57090919 PMC 바로가기 [Article Type] Brief Report
Clinical Differences between COVID-19 and a COVID-Like SyndromeBrief Report Published on 2021-06-072022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] affected Atypical atypical COVID-19 clinical presentation Characteristics characterized clinical Clinical management clinical presentation cohort of patient COVID-19 COVID-19 disease COVID-like syndrome described detectable difference General population greater hospital Hospitalized Infection lung failure nasopharyngeal Nasopharyngeal swab nasopharyngeal swabs NPs pandemic Patient physician Pneumonia positive repeated reported risk of infection SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 viral RNA serological Swab test Symptom syndrome tested virus [DOI] 10.3390/jcm10112519 PMC 바로가기 [Article Type] Brief Report
SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar LavageImmunology Published on 2021-06-042022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] ACE2 angiotensin BAL Bronchoalveolar lavage cause cellular entry contribute correlated downregulation Evidence expression level inducer interferon lavage lung lung bronchoalveolar lavage Lung diseases lung failure macaque mRNA expression naïve observation Pneumonia primary cell PROTECT pulmonary failure receptor reduced Respiratory disease rhesus macaques S1 protein SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 virus shown spike Spike protein suppressed Type type I interferon [DOI] 10.3389/fimmu.2021.658428 PMC 바로가기 [Article Type] Immunology
Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic CandidatesSARS-CoV-2의 다중 신호 전달 경로 표적화: COVID-19 치료 후보에 대한 접근Review Published on 2021-05-142022-09-10 Journal: Molecules [Category] SARS, 치료제, [키워드] Acute coronary syndrome Apoptosis autophagy candidate Candidates Caspases clinical symptom Clinical symptoms combating coronary syndrome coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 develop effective Epidemics Factor highlight Host Inflammation Interaction lung failure mediators Multiple natural products Necrosis Nrf2 nuclear oxidative stress pathogenic pathway Pneumonia remained Replication road SARS-CoV-2 signal signaling pathway signaling pathways targeting therapeutic target therapy TNF-α transduction Treatment strategies Tumor tumor necrosis tumor necrosis factor tumor necrosis factor-α [DOI] 10.3390/molecules26102917 PMC 바로가기 [Article Type] Review
The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial중증 COVID-19 환자에서 N-아세틸시스테인의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-122022-09-10 Journal: Trials [Category] 임상, [키워드] 1:1 Acetylcysteine Activation Acute respiratory infection addition Admission All participant All participants antioxidant effect antioxidant effects appearance approved Arm assigned Bandar Abba Bandar Abbas baseline Blinding block randomization Care caused cell damage clinical clinical condition clinical trial clinical trials Committee comparator Comparator group composite endpoint control group Controlled clinical trial COVID-19 discharge dissemination dose Effects Efficacy element ethics committee evaluate excluded expected FIVE Health Health care help Hospitalization hypersensitivity Hypoxemia infiltration inflammatory factors injection intensive care intensive care unit Intervention intervention group Intravenous injection investigator Lactate lactate dehydrogenase LDH lead Local lung lung failure lymphopenia mechanical ventilation Medical Science Medical Sciences medication minute N-acetylcysteine number objective outcome oxygen oxygen partial pressure parallel-group partial pressure participant Patient patients Pharmaceutical Company Phase 3 Placebo positive PCR test Pregnancy primary endpoint principal investigator Progressive protocol random randomised randomised controlled trial randomization Randomized Randomly reactive oxygen species receive recruitment Registered registry reported respiration rate respiratory infection Saline Sample size SARI SARS-CoV-2 virus sequence severe COVID-19 severe COVID-19 patient severe COVID-19 patients Side effect Standard Standard of care Sterile sterile water Study protocol supplementary material technology test results the ethics committee the patient the SARS-CoV-2 virus Treatment Trial registration university water water for injection website were measured written consent [DOI] 10.1186/s13063-021-05242-4 PMC 바로가기 [Article Type] Letter
AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine stormAntagomiRs: COVID-19 사이토카인 폭풍에 도전하기 위한 새로운 치료 전략Article Published on 2021-04-012022-09-11 Journal: Cytokine & growth factor reviews [Category] MERS, SARS, 진단, 치료제, [키워드] Activation actual antagomiRs ARDS cardiovascular disease characterized clinical manifestations coronavirus COVID-19 COVID-19 cytokine storm COVID-19 pandemic cytokine Cytokine storm Cytokines death demonstrated develop IL-6 lung failure Lungs MicroRNAs organ other coronavirus other coronaviruses reduce reducing Safe secure severe patients specificity target organ the cytokine storm the disease the patient therapeutic strategy therapy Treatment Vaccine widespread [DOI] 10.1016/j.cytogfr.2020.09.001 PMC 바로가기 [Article Type] Article
Extracorporeal life support in COVID‐19‐related acute respiratory distress syndrome: A EuroELSO international surveyMain Text Article Published on 2021-03-282022-10-28 Journal: Artificial organs [Category] COVID-19, SARS, [키워드] acute respiratory distress approved ARDS benefit Clinical improvement Combination country COVID‐19 COVID‐19 patient COVID‐19 COVID‐19‐induced acute respiratory distress syndrome Critically ill patient disease ECMO EuroELSO European Extracorporeal extracorporeal life support extracorporeal membrane oxygenation fraction heart failure Hypoxemia hypoxemic hypoxic respiratory failure Initially International IQR lack less life lung failure major bleeding Mortality MOST Multimorbidity organization outcome pandemic pandemic coronavirus participated Patient performed physician professional question questionnaire recommendation reported required Respiratory failure responsible SARS‐CoV‐2 Severe case shown Support survey time treat Treatment Triage use of ECMO was used [DOI] 10.1111/aor.13940 PMC 바로가기 [Article Type] Main Text Article